Загрузка...
Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials
BACKGROUND/AIMS: Numerous reasons have been identified for why U.S.-based principal investigators choose to not continue participating in FDA-regulated trials. However, unexplored are reasons why a substantial number of principal investigators, facing the same challenges, remain engaged in clinical...
Сохранить в:
| Опубликовано в: : | Contemp Clin Trials Commun |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Elsevier
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6926102/ https://ncbi.nlm.nih.gov/pubmed/31890985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2019.100502 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|